If you or a loved one is taking Tysabri, understanding the early signs of PML is critical. This checklist helps you recognize symptoms like weakness, vision changes, and confusion. Building on decades of research into drug safety, this page translates complex medical guidance into clear, actionable steps.
Building on the general health framework, the specific risk of progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab) exemplifies how a therapeutic agent can create a distinct occupational hazard. Tysabri is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults. Its use carries a well-documented risk of PML, an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, emphasizing that the drug increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefit when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
When PML develops in a patient receiving Tysabri, the prognosis is generally poor. The infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Treatment for severe PML after Tysabri exposure focuses on rapid discontinuation of the drug and supportive care. The FDA label instructs that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In multiple sclerosis patients, an MRI scan should be obtained prior to initiating Tysabri to help differentiate subsequent MS symptoms from PML; in Crohn's disease patients, a baseline brain MRI may also be helpful (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). After discontinuation, patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least six months, as PML has been reported following discontinuation in patients who did not have findings suggestive of PML at the time of stopping Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is a humanized monoclonal antibody that binds to the alpha-4 subunit of integrins, inhibiting the adhesion and migration of leukocytes across the blood-brain barrier. This mechanism reduces inflammatory activity in the central nervous system, which is beneficial for treating multiple sclerosis and Crohn's disease. However, by impairing immune surveillance in the brain, Tysabri creates an environment where the JC virus can reactivate and cause PML. The virus typically remains latent in immunocompetent individuals, but in the setting of reduced T-cell trafficking to the brain, it can replicate and infect oligodendrocytes, leading to demyelination and the characteristic clinical presentation of PML.
The FDA has mandated a boxed warning that clearly states Tysabri increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies specific risk factors—anti-JCV antibodies, duration of therapy, and prior immunosuppressant use—and instructs healthcare professionals to monitor patients and withhold Tysabri at the first sign of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program further restricts distribution to ensure that prescribers and patients are informed of the risks. These measures represent a comprehensive risk communication strategy, though the inherent severity of PML means that even with adequate warnings, affected patients face a poor prognosis.
PML can occur at any time during Tysabri treatment, but risk increases with longer duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The infection may also manifest after discontinuation, as the label notes that PML has been reported in patients who did not have findings suggestive of PML at the time of stopping Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This delayed presentation underscores the need for continued monitoring for at least six months after cessation. The clinical course of PML is typically progressive, with symptoms such as cognitive decline, motor deficits, and visual disturbances worsening over weeks to months. Without effective antiviral therapy, the infection often leads to severe disability or death.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The prognosis for severe PML after Tysabri is generally poor, with the infection usually leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early detection and immediate discontinuation of Tysabri are critical, but even with supportive care, outcomes are often unfavorable.
Treatment for severe PML after Tysabri focuses on rapid discontinuation of the drug and supportive care. The FDA label instructs that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). After discontinuation, patients should be monitored for at least six months for any new signs of PML.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.